Roche Holding Ltd ADR (RHO6y)

40.340
-0.305(-0.75%)
  • Volume:
    0
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    40.340 - 40.340
  • Type:Equity
  • Market:Germany
  • ISIN:US7711951043
  • WKN:891106

RHO6y Overview

Prev. Close
40.645
Day's Range
40.34-40.34
Revenue
82.71B
Open
40.34
52 wk Range
32.595-41.995
EPS
-
Volume
0
Market Cap
287.91B
Dividend (Yield)
1.01
(2.48%)
Average Vol. (3m)
327
P/E Ratio
-
Beta
-
1-Year Change
9.6%
Shares Outstanding
854,260,903
Next Earnings Date
-
What is your sentiment on Roche Holding Ltd DRC?
or
Market is currently closed. Voting is open during market hours.

Roche Holding Ltd DRC News

Roche Holding Ltd DRC Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralNeutralSellBuyStrong Buy
Technical IndicatorsStrong BuyBuyBuyBuyStrong Buy
SummaryBuyNeutralNeutralBuyStrong Buy

Roche Holding Ltd DRC Company Profile

Roche Holding Ltd DRC Company Profile

Employees
101465

Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women’s health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. The company has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors, as well as with Surface Oncology, Inc. to evaluate SRF388. It also has a clinical collaboration with Carrick Therapeutics, Ltd. to evaluate a novel combination of Carrick’s samuraciclib and its giredestrant in CDK4/6i resistant HR+, HER2- metastatic breast cancer. The company was founded in 1896 and is headquartered in Basel, Switzerland.

Read More
  • it will go up: the chart formed an "bulllish doji star"
    0
    • This Is one and only real competitor in covid test from POLAND http://scopefluidics.com/scope-fluidics-is-developing-an-ultra-fast-covid-19-panel-for-its-pcrone-rapid-molecular-diagnostic-system/
      0
      • Roche just announced as the test pushed through for Covid 19 Tessting. Up Up Up!
        1
        • Jan 26, 2020 Sun $41.20 its GENE is dazzling as always focusing on breakthrough sciences
          0
          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.